

Cancer Outcomes and Services Dataset An update


Colorectal NSSG workshop

April 2013



Timetable





A recap - COSD




- Replaces submission to cancer registries
- Trigger is new diagnosis/updates
- Can be submitted from different sources
- Submitted monthly
- RCPath extracted from reports
- Aligned with national audits

A recap – Cancer registration



- National Cancer Registration Service
- Will have single system and processes
- Will collate data from different sources
- will provide regular feedback
- Separation of registration and analysis within PHE



Core data



- Updated generic dataset for whole patient pathway
- Cancer Waits items apply to all cases
 - Referral section
 - METASTATIC SITE (at diagnosis)
- New CORE data items
 - DATE OF DIAGNOSIS (CLINICALLY AGREED)
 - CANCER SYMPTOMS FIRST NOTED DATE (CTYA only)
 - MORPHOLOGY (ICDO3) Haem only
 - ACE 27 SCORE (Optional)
 - CLINICAL NURSE SPECIALIST
 - TNM EDITION NUMBER
 - MONITORING INTENT (Urology and Lung)

Key site specific colorectal data



- Imaging dates
 - First CT scan
 - MRI scans (rectal pre treatment and post neoadjuvant)
 - Endoanal Ultrasound
- Synchronous tumours
- BMI
- Duke's Stage
 - (TNM also collected in generic data)
- Type of Surgical access
 - Laparoscopic/open/converted
- Other key pathology items
 - Components used to calculate Stage

Standard monthly feedback reports



- By MDT/Tumour group and Provider for month of diagnosis
- Available within month of submission
- Breakdown by:
 - Number of new diagnoses
 - Number of patients treated
 - Basis of diagnosis
 - Stage
 - Performance status completed

Reporting Portal



	Α	В	С	D	Е	F	G	Н
54	L2.3d	Breakdown of stage by tumour group and percentage with completed						
55		stage grouping						
56		Diagnosed	% Staged	Stage 1	Stage 2	Stage 3	Stage 4	Other Stage
57	Brain/Central Nervous System (invasiv	0		0	0	0	0	0
58	Breast (invasive)	11	55%	3	2	1	0	0
59	Colorectal (invasive)	13	100%	0	5	6	0	2
60	Gynaecological (invasive)	11	73%	0	0	0	0	8
61	Haematological (invasive)	19	0%	0	0	0	0	0
62	Head and Neck (invasive)	8	88%	1	2	0	4	0
63	Lung (invasive)	20	90%	0	0	0	0	18
64	Sarcoma (invasive)	0		0	0	0	0	0
65	Skin (invasive)	0		0	0	0	0	0
66	Upper Gastrointestinal (invasive)	10	30%	0	0	1	2	0
67	Urological (invasive)	78	55%	10	8	6	2	17
68	Other (invasive)	4	25%	1	0	0	0	0
69	L2.3e	Percentage with Performance Status field populated						
70	Number diagnosed (from L2.3a)	224						
71	Number with Performance Status	204						
72	% with Performance Status	91%						
73	L2.3f	Breakdown of basis of diagnosis by tumour group						
74		Clinical Diagnosis	Clinical Invest.	Specific Tumour Marker	Cytology	Histology (Metasta sis)	Histology (Primary)	
75	Brain/Central Nervous System (invasiv	0	0	0	0	0	0	0
76	Breast (invasive)	0	0	0	1	0	10	0
77	Colorectal (invasive)	0	0	0	0	0	13	0
78	Gynaecological (invasive)	0	0	0	0	0	11	0
79	Haematological (invasive)	7	7	1	2	0	2	0
80	Head and Neck (invasive)	0	1	0	0	0	7	0
81	Lung (invasive)	1	3	0	0	1	15	0

Compiled monthly summary reports



- By MDT/Tumour group and Provider for month of diagnosis
- Available within six months of submission
- Breakdown by:
 - Diagnosis
 - Treatment type
 - Basis of diagnosis
 - Stage
 - Performance Status
 - Completion of pathology data
 - ???other relevant site specific feedback


Clinical reports



- Development begins this year
- Consultation with clinical teams
 - Colorectal SSCRG
 - Network site specific groups
- Need to align with
 - Service profiles
 - Peer review clinical lines of enquiry
 - National and professional body audits

Timetable







Thank you

Queries to: cosd@ncin.org.uk